Skip to main content
NVDA0.00%AAPL-0.04%GOOGL-3.15%MSFT0.00%AMZN+0.10%TSM-4.52%SPCX-9.14%META-0.52%AVGO-4.31%TSLA-0.38%LLY+2.83%BRK-B+1.50%MU-1.05%WMT+2.82%SKHY-8.07%JPM+0.40%AMD-8.10%V+1.59%XOM+0.08%JNJ+3.81%ASMLa-4.74%MA+1.70%ABBV+0.03%INTC-8.04%COST+1.99%CVX-0.04%0700.HK-2.89%1398.HK-1.34%CSCO-2.21%KO+2.87%PG+5.58%UNH+1.91%ORCL-2.80%BAC+0.59%1816.HK-0.22%3988.HK-1.80%HD+4.33%CAT-4.89%0005.HK-1.23%PM+2.17%HSBA.L-2.45%0857.HK-0.82%GE-0.79%AP2d-6.79%1288.HK-0.30%0939.HK-0.61%AMAT-8.16%NVS+1.52%MS-1.63%DELL-6.78%PLNJPY-1.46%EURAUD-1.28%EURCAD-1.15%AUDUSD+1.06%EURJPY-0.96%USDCAD-0.91%USDTHB+0.86%SGDJPY-0.84%GBPZAR+0.78%USDJPY-0.77%USDZAR+0.77%EURNZD-0.75%EURGBP-0.75%CHFSEK+0.73%AUDCHF+0.64%USDPLN+0.64%EURCHF-0.62%EURZAR+0.58%NZDUSD+0.54%NOKJPY-0.54%GBPAUD-0.53%GBPUSD+0.53%AUDNZD+0.52%CADCHF+0.52%EURNOK-0.48%CHFSGD+0.46%EURPLN+0.45%AUDNOK-0.43%GBPCAD-0.42%GBPTRY+0.41%USDCHF-0.41%NZDCAD-0.39%CHFJPY-0.38%AUDJPY+0.33%NZDSGD-0.32%GBPHKD+0.32%EURHKD-0.31%USDNOK-0.30%GBPMXN-0.28%USDSEK+0.27%NZDJPY-0.24%GBPJPY-0.24%EURUSD-0.22%USDTRY+0.20%USDCNH-0.20%EURCNH-0.19%USDMXN+0.18%CADJPY+0.18%EURSGD-0.17%USDDKK+0.17%USDILS+0.16%NZDMXN-0.15%CHFNOK+0.15%USDHKD-0.15%AUDCAD+0.14%AUDSGD-0.13%NZDCHF+0.12%GBPCHF+0.11%EURSEK+0.10%EURCZK+0.05%AUDDKK+0.04%USDCOP-0.04%GBPNZD-0.03%GBPSGD+0.02%EURDKK-0.01%USDSGD0.00%GAGUSD-5.89%XAGUSD-5.89%XPTUSD-4.00%GAUUSD-2.84%XAUUSD-2.84%HG1-2.70%UKOIL+2.43%USOIL+1.35%SUGAR0.00%XNGUSD0.00%COFFEE0.00%COCOA0.00%BTCUSD-3.35%ETHUSD+16.36%USDTUSD-0.02%XRPUSD+9.91%SOLUSD+10.75%TRXUSDT-0.75%ZECUSDT-7.95%DOGEUSD+14.39%XMRUSDT-1.77%LINKUSD+14.52%XLMUSD-4.59%BCHUSDT-4.51%LTCUSD+8.69%UNIUSD-6.06%SUIUSD-5.62%HBARUSDT-6.18%TONUSD+26.39%TAOUSDT-5.75%AAVEUSD-5.52%DOTUSDT-3.05%ICPUSDT-6.22%WLDUSDT-7.21%ONDOUSDT-7.19%ARBUSDT-4.79%JUPUSDT-5.17%ATOMUSDT-3.26%INJUSDT-8.12%STXUSDT-11.12%TIAUSDT-6.23%FETUSDT-6.08%PYTHUSDT-7.51%SEIUSDT-9.27%IMXUSDT-7.91%GRTUSDT-6.54%OPUSDT-8.75%WIFUSDT-6.99%IOTAUSDT-5.48%AXSUSDT-5.93%POLUSDT-4.92%FARTCOINUSDT-5.87%EOSUSDT-2.04%DYDXUSDT-6.41%GALAUSDT-5.09%ORDIUSDT-3.33%RONINUSDT-5.30%NOTUSDT-4.94%NVDA0.00%AAPL-0.04%GOOGL-3.15%MSFT0.00%AMZN+0.10%TSM-4.52%SPCX-9.14%META-0.52%AVGO-4.31%TSLA-0.38%LLY+2.83%BRK-B+1.50%MU-1.05%WMT+2.82%SKHY-8.07%JPM+0.40%AMD-8.10%V+1.59%XOM+0.08%JNJ+3.81%ASMLa-4.74%MA+1.70%ABBV+0.03%INTC-8.04%COST+1.99%CVX-0.04%0700.HK-2.89%1398.HK-1.34%CSCO-2.21%KO+2.87%PG+5.58%UNH+1.91%ORCL-2.80%BAC+0.59%1816.HK-0.22%3988.HK-1.80%HD+4.33%CAT-4.89%0005.HK-1.23%PM+2.17%HSBA.L-2.45%0857.HK-0.82%GE-0.79%AP2d-6.79%1288.HK-0.30%0939.HK-0.61%AMAT-8.16%NVS+1.52%MS-1.63%DELL-6.78%PLNJPY-1.46%EURAUD-1.28%EURCAD-1.15%AUDUSD+1.06%EURJPY-0.96%USDCAD-0.91%USDTHB+0.86%SGDJPY-0.84%GBPZAR+0.78%USDJPY-0.77%USDZAR+0.77%EURNZD-0.75%EURGBP-0.75%CHFSEK+0.73%AUDCHF+0.64%USDPLN+0.64%EURCHF-0.62%EURZAR+0.58%NZDUSD+0.54%NOKJPY-0.54%GBPAUD-0.53%GBPUSD+0.53%AUDNZD+0.52%CADCHF+0.52%EURNOK-0.48%CHFSGD+0.46%EURPLN+0.45%AUDNOK-0.43%GBPCAD-0.42%GBPTRY+0.41%USDCHF-0.41%NZDCAD-0.39%CHFJPY-0.38%AUDJPY+0.33%NZDSGD-0.32%GBPHKD+0.32%EURHKD-0.31%USDNOK-0.30%GBPMXN-0.28%USDSEK+0.27%NZDJPY-0.24%GBPJPY-0.24%EURUSD-0.22%USDTRY+0.20%USDCNH-0.20%EURCNH-0.19%USDMXN+0.18%CADJPY+0.18%EURSGD-0.17%USDDKK+0.17%USDILS+0.16%NZDMXN-0.15%CHFNOK+0.15%USDHKD-0.15%AUDCAD+0.14%AUDSGD-0.13%NZDCHF+0.12%GBPCHF+0.11%EURSEK+0.10%EURCZK+0.05%AUDDKK+0.04%USDCOP-0.04%GBPNZD-0.03%GBPSGD+0.02%EURDKK-0.01%USDSGD0.00%GAGUSD-5.89%XAGUSD-5.89%XPTUSD-4.00%GAUUSD-2.84%XAUUSD-2.84%HG1-2.70%UKOIL+2.43%USOIL+1.35%SUGAR0.00%XNGUSD0.00%COFFEE0.00%COCOA0.00%BTCUSD-3.35%ETHUSD+16.36%USDTUSD-0.02%XRPUSD+9.91%SOLUSD+10.75%TRXUSDT-0.75%ZECUSDT-7.95%DOGEUSD+14.39%XMRUSDT-1.77%LINKUSD+14.52%XLMUSD-4.59%BCHUSDT-4.51%LTCUSD+8.69%UNIUSD-6.06%SUIUSD-5.62%HBARUSDT-6.18%TONUSD+26.39%TAOUSDT-5.75%AAVEUSD-5.52%DOTUSDT-3.05%ICPUSDT-6.22%WLDUSDT-7.21%ONDOUSDT-7.19%ARBUSDT-4.79%JUPUSDT-5.17%ATOMUSDT-3.26%INJUSDT-8.12%STXUSDT-11.12%TIAUSDT-6.23%FETUSDT-6.08%PYTHUSDT-7.51%SEIUSDT-9.27%IMXUSDT-7.91%GRTUSDT-6.54%OPUSDT-8.75%WIFUSDT-6.99%IOTAUSDT-5.48%AXSUSDT-5.93%POLUSDT-4.92%FARTCOINUSDT-5.87%EOSUSDT-2.04%DYDXUSDT-6.41%GALAUSDT-5.09%ORDIUSDT-3.33%RONINUSDT-5.30%NOTUSDT-4.94%
AT

Anika Therapeutics, Inc. (ANIK)

NASDAQ • Healthcare

$21.09
+$0.48 (+2.4%)
Market closed

Last close at October 22, 2026 at 20:00 UTC

Open$20.76
Day Range$20.63 - $21.02
Avg. Volume (3M)109.2K
Market Cap$276.4M
52 Week Range
$9.01$22.88
Next EarningsIn 13 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$32.6M100%
Gross Profitminus cost of goods$21.2M65%
Operating Incomeminus R&D and overhead$2.9M9%
Net Incomeminus taxes and the rest$3.3M10%

In plain terms: out of every $100 in revenue, Anika Therapeutics, Inc. keeps $10 as net profit.

Fundamentals & Financials

Revenue (TTM)
$120.6M
Net Income (TTM)
-$3.7M
EPS (TTM)
-$0.27
ROA (TTM)
-2.06%
Current Ratio
4.48
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+348.0%Q1 2026$0.31
+485.7%Q2 2026$0.27
+1300.0%Q3 2026$0.42
Next

Nov 4

in 13 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +1300.0%

Anika Therapeutics topped revenue expectations as sales rose 15.6% to about $32.6 million in the second fiscal quarter of 2026, reported July 29, 2026, with revenue of $32.6 million topping the $29.2 million estimate (+11.6%) and up from about $28.2 million a year ago. The company posted adjusted EPS of $0.42, improving from -$0.13 a year ago, alongside gross profit of about $21.2 million and gross margin of roughly 65%. Cash generation was pressured in the period, with negative operating cash flow of roughly $0.7 million, while the company repurchased about $0.9 million of stock. Consensus for the next period calls for EPS of $0.17 on revenue of $29.7 million.

Next report — what to expect

Anika Therapeutics, Inc. (ANIK) reports on November 4, 2026. Wall Street is looking for consensus EPS of $0.42 on consensus revenue of $29.4 million. For trailing context, revenue grew +15.6% year over year last quarter. ANIK has beaten EPS in 4 of 8 most recent quarters, so attention may center on whether results align with those estimates.

View full earnings history

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. develops, manufactures, and commercializes therapeutic products for musculoskeletal care and other medical uses, trading on the NASDAQ as ANIK. In healthcare, the company focuses on injectable osteoarthritis treatments, joint preservation, regenerative and repair products, and recorded $112.8 million of revenue in FY2025.

Name
Anika Therapeutics, Inc.
CEO
Stephen D. Griffin
Website
www.anika.com
Industry
Healthcare
Year Founded
1983
Employees
235

Today's Snapshot

AI-generated

ANIK closed 2.4% higher at 21.09, in line with a firmer sector. Trading was lighter than usual, with volume about half of its usual level. Anika will release third-quarter financial results before the market opens on Nov. 6.

Trading Volume

Below 10d avg (114.0K)

61.4K

vs S&P 500 Today

Strong Outperformance

+3.64%

Updated: October 22, 2026 at 20:25 UTC

Technical Indicators

6 Buy1 Neutral1 Sell
ANIK presents a constructive technical profile with broad moving-average support: the price sits above the short-, medium- and long-term averages, and the classic pivot is comfortably below current levels. Momentum measures including CCI and MACD are positive and on the buy side, while RSI is supportive without extreme readings. Volume trends are favorable, with OBV showing accumulation, although ADX remains modest, indicating the trend’s strength is limited. Volatility is moderate by ATR. Technical takeaway: overall stance is Buy as momentum and volume back a price that is trading above its key moving averages.
All signals
  • EMA (5 indicators)$16.02 - $20.40
    Buy
  • RSI (14)58.76
    Neutral
  • Stochastic %K (14, 3, 3)90.71
    Sell
  • MACD Level (12, 26)0.09
    Buy

Peers & Related Assets

MXCTMaxCyte, Inc.
$1.43-2.7%
ARAYAccuray Incorporated
$0.13-3.7%
AVRAnteris Technologies Global Corp.
QIPTQuipt Home Medical Corp.
OWLTOwlet, Inc.
APYXApyx Medical Corporation
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.